Gregory C. Critchfield, MD, MS
Chairman, President, and CEO
“The work that Sera Prognostics is doing is groundbreaking and game-changing. It was so important to me to be a part of this effort that I left retirement to help Sera develop technologies to improve outcomes for mothers and their babies.” Dr. Critchfield joined the Sera Prognostics Board of Directors in August 2010, became Chairman in April 2011, and was appointed as Sera’s CEO in November 2011. Before joining Sera, Dr. Critchfield was president of Myriad Genetics Laboratories from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Myriad, he served as senior vice president/chief medical and science officer at Corning Clinical Laboratories/Quest Diagnostics. Dr. Critchfield currently serves on the boards of Integrated Diagnostics, Nodality, and Metamark Genetics. He holds a B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.
Durlin E. Hickok, MD, MPH
Senior Vice President and Chief Medical Officer
“I have been working on preventing prematurity and other pregnancy complications my entire career. Finally, with a simple blood test, we have the hope of making a dramatic difference.” Dr. Hickok is the former senior vice president and chief medical officer of ProteoGenix, Inc., a company focused on developing diagnostics for pregnancy and neonatal management. Prior to joining ProteoGenix, he served as senior vice president at Adeza Biomedical and part of the management team that successfully developed the fetal fibronectin test for prediction of preterm birth, which was acquired by Cytyc Corporation in 2007. Dr. Hickok has authored more than 80 publications on topics including preterm delivery, preeclampsia, and other aspects of pregnancy care and testing. Dr. Hickok’s residency and fellowship training were at the University of Washington, Department of Obstetrics and Gynecology. He also received a masters degree in Public Health through the Robert Wood Johnson Clinical Scholars Program.
Jay Boniface, PHD
Chief Scientific Officer
"At Sera, I can draw upon my training in protein biochemistry, proteomics, reproductive endocrinology, and biomarker discovery to enable product development in unmet areas of women’s health. I can do so surrounded by employees, leadership, and investors that repeatedly ask: 'what is best for the patient' and are committed to solving challenging health problems with high standards of ethics." Dr. Boniface previously served as scientist and program director for a number of biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals, and Eos Biotechnology. Dr. Boniface earned his Ph.D. in biochemistry at Albany Medical College and was a postdoctoral scholar in molecular immunology at Stanford University.
Nadia F. Altomare
Chief Commercial Officer
"I am inspired by the innovation of Sera’s technology and I believe that we can lead the way to decrease the frequency and severity of preterm birth, and importantly, advocate for a new standard to detect premature birth early." Nadia Altomare has more than 20 years of women’s healthcare experience and an extensive knowledge in developing and implementing strategic plans to drive commercial growth in the life sciences, biotechnology, and diagnostic industries. Ms. Altomare has held senior management positions in single and multi-product/service environments spanning from entrepreneurial to Fortune 500 companies. Ms. Altomare served as chief executive officer of an early detection of cancer diagnostics company, Abcodia Limited, where she shaped the global commercial, regulatory and fundraising strategies for the business. In addition, she served as vice president and general manager of the DNA analysis business at ThermoFisher Scientific (formerly Life Technologies) and also held leadership roles at PerkinElmer, including as the vice president & general manager of the cytogenetic DNA testing and as vice president of commercial operations, where she integrated the ViaCord acquisition into the broader diagnostic unit.
Andrew A. Sauter
Chief Financial Officer
“I am proud to be part of something that will change the face of medicine.” Mr. Sauter was formerly the chief financial officer for Avigen, a publicly traded biopharmaceutical company. In December 2009, Mr. Sauter oversaw the final sale of the company to a strategic buyer through a structured transaction. Previously, he was an auditor at Ernst & Young and a finance manager at Bank of America. Mr. Sauter holds a B.A. in Economics and Accounting from Claremont McKenna College.
Douglas Fisher, MD
Chief Business Officer
“I have been involved with a number of women’s health companies, but none of them will impact patients’ lives more than Sera. Developing tests that predict pregnancy complications will enable improved disease management and benefit thousands, if not millions, of women and their babies.” Dr. Fisher is a former partner of InterWest Partners, LLC, and served on Sera’s Board of Directors since the company’s Series A funding in November 2011. He joined Sera as its business and strategy development executive in January 2015 and continues to serve as an Executive-in-Residence at InterWest Partners. Dr. Fisher has focused on biopharmaceutical, diagnostic, and medical device investments throughout his career, working in venture capital, consulting, and pharmaceutical industries. He received his M.D. and M.B.A. from the School of Medicine and the Wharton School, respectively, at the University of Pennsylvania.